Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Chemotherapy or immunosuppressive treatment may reactivate HBV

Chemotherapy or immunosuppressive treatment may reactivate HBV

Antibodies used in research lab should be made by recombinant DNA technology, say authors

Antibodies used in research lab should be made by recombinant DNA technology, say authors

COMBACTE-MAGNET project launched to study new treatment options for infections caused by MDR-GNB

COMBACTE-MAGNET project launched to study new treatment options for infections caused by MDR-GNB

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

New experimental study shows immunotherapy can reduce acute effects of heroin

New experimental study shows immunotherapy can reduce acute effects of heroin

Changes in current Ebola virus epidemic could potentially interfere with experimental treatments

Changes in current Ebola virus epidemic could potentially interfere with experimental treatments

Solvanix set up to commercialise novel antibody-stabilisation technology

Solvanix set up to commercialise novel antibody-stabilisation technology

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

EMA accepts Praluent (alirocumab) MAA for review

EMA accepts Praluent (alirocumab) MAA for review

Two new ODYSSEY trials meet primary efficacy endpoints

Two new ODYSSEY trials meet primary efficacy endpoints

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

High speed, high resolution glycan mapping now achievable for mAb characterization

High speed, high resolution glycan mapping now achievable for mAb characterization

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

CMC Biologics, OncoSynergy partner to develop novel potential treatment for Ebola

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

Curie-Cancer, GamaMabs Pharma extend partnership to develop 3C23K drug for gynecological cancers

PD-L1 expression tied to favourable prognosis in SCLC

PD-L1 expression tied to favourable prognosis in SCLC

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Vaccinex completes VX15/2503 Phase 1 clinical trial in patients with advanced, refractory solid tumors

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.